Approved indications (U.S.):

• Cryopyrin‑Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle‑Wells syndrome, in adults and pediatric patients 12 years and older.
• Recurrent pericarditis (RP) and reduction in risk of recurrence in adults and pediatric patients 12 years and older.
• Maintenance of remission of Deficiency of Interleukin‑1 Receptor Antagonist (DIRA) in adults and pediatric patients weighing at least 10 kg.

Off‑label uses and evidence:

• Gout flare prevention when starting urate‑lowering therapy: several phase II–III trials show once‑weekly rilonacept markedly reduces the number of gout flares compared with placebo, but this use is not FDA‑approved.
• Other inflammatory or autoimmune conditions (for example some rare autoinflammatory or connective‑tissue diseases) have been studied only in small or early‑phase trials, with mixed or limited benefit, so routine use is not established.

Efficacy expectations:

• Recurrent pericarditis: pain and inflammation often improve quickly, with median time to meaningful pain relief about 5 days and C‑reactive protein (CRP) normalization about 7 days after starting therapy; in a pivotal trial, rilonacept reduced the risk of recurrent pericarditis episodes by over 90% compared with placebo and allowed most patients to taper off steroids.
• CAPS and DIRA: many patients experience substantial reduction in fevers, rash, joint pain, and inflammatory markers within days to weeks, with sustained control while continuing weekly injections.
• Compared with other IL‑1 blockers (such as anakinra or canakinumab), Arcalyst offers convenient once‑weekly dosing and strong data for CAPS and recurrent pericarditis; choice among agents depends on diagnosis, prior response, dosing preference, cost, and clinician experience.

General administration: Arcalyst is given as a subcutaneous (under‑the‑skin) injection, usually once weekly, using a solution prepared by mixing the powdered medicine in the vial with sterile water; the first dose is typically administered and taught by a healthcare professional, after which many patients or caregivers can self‑inject at home as instructed.

Typical dosing by condition and age:

• CAPS and recurrent pericarditis – adults: loading dose 320 mg (two 160 mg injections at different sites on the same day), then 160 mg as a single injection once weekly.
• CAPS and recurrent pericarditis – ages 12–17 years: loading dose 4.4 mg/kg up to a maximum of 320 mg (given as one or two injections), then 2.2 mg/kg up to a maximum of 160 mg once weekly.
• DIRA – adults and pediatric patients ≥10 kg: 4.4 mg/kg up to a maximum of 320 mg once weekly, given as one or two injections; there is not a separate loading and maintenance dose.

How to take it: Injections are usually given in the abdomen, thigh, or upper arm, rotating sites each week; they can be given without regard to food, and many patients pick the same day each week to simplify the schedule and maintain steady drug levels.

Special dosing instructions: The total volume per injection site is limited (up to 2 mL), so larger doses may need to be split into two injections; dose adjustments, if needed, are individualized based on response and tolerability and should only be made by the prescriber.

Missed dose: If you miss a dose, contact your healthcare provider for instructions rather than automatically doubling or quickly repeating a dose; they may advise you to take the missed dose as soon as remembered or wait until the next scheduled injection depending on timing.

Overdose: There is no specific antidote; if too much Arcalyst is taken or extra injections are given, seek medical care or contact a poison control center right away so you can be monitored for side effects such as infection or severe injection reactions.

Common side effects:

• Injection‑site reactions (redness, pain, swelling, itching, bruising, small lumps, warmth, or rash where the shot is given) are the most frequent, usually mild to moderate and lasting 1–2 days.
• Upper respiratory infections (such as runny or stuffy nose, sore throat, cough, ear infections) and mild rash, joint or muscle aches can occur; these are generally manageable but should be reported if persistent or severe.

Serious or rare adverse effects needing immediate medical attention:

• Serious infections, including pneumonia, opportunistic infections, or possibly tuberculosis, may occur because Arcalyst suppresses part of the immune response; symptoms such as high fever, chills, shortness of breath, severe cough, stiff neck, or feeling very ill require urgent evaluation.
• Severe allergic or hypersensitivity reactions (trouble breathing, swelling of face, lips, tongue or throat, widespread rash or hives, severe dizziness) are uncommon but require stopping the drug and emergency care.
• Long‑term immune suppression may slightly increase the risk of some cancers, though the exact risk with Arcalyst is not fully known.

Warnings and precautions:

• Do not start Arcalyst if you have an active or chronic serious infection; treatment should be stopped if a serious infection develops.
• Other biologic immune‑suppressing drugs that block IL‑1 (such as anakinra or canakinumab) or tumor necrosis factor (TNF) (such as etanercept, adalimumab, infliximab) should generally not be used at the same time because of a higher risk of serious infection.
• Cholesterol and triglycerides often rise after inflammation is controlled; lipid levels are usually checked and treated according to standard cardiovascular‑risk guidelines.
• Pregnancy: human data are very limited and animal studies suggest potential fetal risk, so use in pregnancy is generally avoided unless the expected benefit clearly outweighs the risk and other options are inadequate.
• Breastfeeding: it is unknown whether rilonacept passes into human milk; decisions about breastfeeding should balance the mother’s need for treatment, disease control, and any potential risk to the infant.
• Older adults or people with a history of frequent infections, diabetes, chronic lung disease, or other conditions that increase infection risk should be monitored especially closely.

Relative safety compared with similar drugs: Overall, the safety profile of Arcalyst is similar to other IL‑1 blockers, with injection‑site reactions and mild respiratory infections most common; its once‑weekly dosing does not appear to increase serious adverse events compared with daily or monthly IL‑1 agents in available studies.

Side‑effect reporting and safety updates: Patients should promptly inform their prescriber about any side effects, particularly signs of infection or allergic reaction; side effects can also be reported directly to the FDA through the MedWatch program, and new safety information is posted periodically in product labeling and FDA safety communications.

Drug and biologic interactions:

• Using Arcalyst with other IL‑1 blockers (such as anakinra or canakinumab) or TNF inhibitors (such as etanercept, adalimumab, infliximab) is generally avoided because combining these biologics significantly increases the risk of serious infections.
• Arcalyst may affect how the liver processes some medicines that are metabolized by cytochrome P450 enzymes; for drugs with a narrow therapeutic range (for example warfarin and certain anti‑seizure or transplant medicines), clinicians may monitor drug levels or clinical effect more closely and adjust doses if needed.
• No specific food or alcohol interactions are known, but heavy alcohol use can further impair immune function and is usually discouraged in people on immunomodulatory therapy.

Vaccines and diagnostic procedures:

• Live vaccines (such as certain shingles, measles‑mumps‑rubella, or intranasal flu vaccines) should be avoided while taking Arcalyst; recommended vaccines are usually updated before starting therapy.
• Inactivated vaccines (such as standard flu or COVID‑19 shots) are generally considered safe but may be less effective because the immune response is partially suppressed.
• There are no specific interactions with imaging contrast agents or routine diagnostic procedures beyond the usual infection‑risk considerations.

Conditions and co‑medications requiring caution:

• History of recurrent or chronic infections, untreated or latent tuberculosis, or significant immunosuppression from other drugs or illnesses increases risk and requires careful evaluation before starting Arcalyst.
• People with uncontrolled diabetes, chronic lung disease, advanced kidney or liver disease, or malignancy may have higher baseline infection risk; prescribers typically weigh risks and benefits and may monitor more closely.
• Concomitant use with other systemic immunosuppressants (high‑dose steroids, some chemotherapy or biologics) can compound infection risk and should be carefully justified and monitored.

Monitoring while on therapy:

• Periodic blood tests are often done to check lipid levels (cholesterol and triglycerides) and, when clinically indicated, markers of inflammation and basic blood counts.
• Clinicians also monitor for signs and symptoms of infection or hypersensitivity at each visit, and may screen for tuberculosis or chronic infections before starting in higher‑risk patients.

Q: What conditions does Arcalyst treat?
A: Arcalyst is approved to treat certain rare autoinflammatory diseases (CAPS and DIRA) and recurrent pericarditis, and it is sometimes used off‑label for other IL‑1–driven conditions when supported by specialist judgment and available evidence.

Q: How quickly will I feel better after starting Arcalyst?
A: Many people with recurrent pericarditis or CAPS notice less pain and systemic symptoms within a few days, with most trial participants achieving clear pain improvement by about 5 days and normalization of inflammation blood tests within about a week.

Q: How long do I need to stay on Arcalyst for recurrent pericarditis?
A: Duration is individualized, but studies show that continuing weekly treatment keeps most patients free of recurrences, and stopping therapy can lead to flares in many people, so cardiologists often maintain treatment for many months or longer before considering a cautious taper.

Q: Does Arcalyst weaken my immune system?
A: Arcalyst selectively blocks IL‑1, an important inflammatory signal, so it can increase your risk of infections, but it does not suppress all aspects of immunity; staying current on non‑live vaccines, promptly reporting infections, and avoiding combinations with other strong biologic immunosuppressants helps manage this risk.

Q: Can I get vaccines while taking Arcalyst?
A: Live vaccines should generally be avoided during treatment, but most inactivated vaccines can still be given, and many clinicians prefer to update needed vaccines before you start Arcalyst; always review vaccine plans with your prescriber.

Q: Is Arcalyst safe during pregnancy or breastfeeding?
A: Because human data are limited and animal studies suggest possible fetal risk, Arcalyst is usually avoided in pregnancy unless clearly necessary, and its use while breastfeeding requires a careful risk–benefit discussion with your specialist.

Storage: Keep Arcalyst vials in their original carton in the refrigerator at 36–46°F (2–8°C), protected from light, and do not freeze; after mixing with sterile water, the solution may be kept at room temperature, protected from light, and used within 3 hours, then discard any leftover medicine.

Handling at home: Store out of reach of children and pets, do not use past the expiration date, and do not use vials that look damaged or were left warm or outside the recommended temperature range unless your provider or specialty pharmacy confirms they are safe.

Disposal: Place used needles and syringes in a puncture‑resistant sharps container, and throw away unused or expired vials and supplies according to local pharmacy or community take‑back guidance—do not flush medicines down the toilet or pour them down a drain unless specifically instructed.